NCT01526746已完成1 期
An Open-Label, Single-Dose, Parallel-Group Study to Compare the Pharmacokinetics of Tasimelteon in Subjects With Renal Impairment With That in Matched Control Subjects With Relatively Normal Renal Function
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 32
- 试验地点
- 3
- 主要终点
- Tasimelteon pharmacokinetic parameters (AUC, Cmax, Tmax)
研究概览
简要总结
The purpose of this research study is to understand whether there is any difference in the amount of tasimelteon (including its breakdown products) in the blood of individuals with severe renal impairment compared to individuals who have normal renal function. The safety and tolerability of tasimelteon will also be assessed throughout this study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 79 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Ability and acceptance to provide written informed consent;
- •Men or women between 18 - 79 years, inclusive;
- •Subjects with Body Mass Index (BMI) of >18 and <40 kg/m2 (BMI = weight (kg)/ [height (m)]2);
- •Males, non-fecund females (i.e., surgically sterilized, if procedure was done 6 months before screening or subject is postmenopausal, without menses for 6 months before screening), or females of child-bearing potential using an acceptable method of birth control for a period of 35 days before the first dosing and have a negative pregnancy test at the screening and baseline visits; Note 1: Acceptable methods of birth control include any one of the following: abstinence, vasectomized sexual partner, hormonal methods (i.e. pill, hormonal IUD, Depo-Provera, implants, patch, intravaginal device [NuvaRing]), intrauterine device (IUD [copper banded coils]), diaphragm, cervical cap, or condom with spermicidal jelly or foam.
- •Willing and able to comply with study requirements and restrictions;
- •Groups 1- 2 (renal impairment)
- •Subjects with renal impairment defined as
- •Group 1: Stage 5 End Stage Renal Disease (ESRD) (eGFR < 15 mL/min/m2) requiring regularly scheduled dialysis and have been on a stable dialysis regimen for at least three months at baseline; OR
- •Group 2: Stage 4 severe renal impairment (eGFR ≤ 29 mL/min/m2) but not requiring dialysis as calculated using the Modification of Diet in Renal Disease (MDRD) Equation (Appendix 18.3)
- •Otherwise considered healthy in general as determined by past medical history, physical examination, vital signs, electrocardiogram, and laboratory tests at screening;
- •Vital signs (after 3 minutes resting in a semi-supine position) which are within the ranges shown below.
- •Body temperature between 35.0-37.5 °C;
- •Systolic blood pressure between 100-180 mmHg;
- •Diastolic blood pressure between 60-115 mmHg;
- •Pulse rate between 40-100 bpm.
- •Group 3 (healthy matched controls)
- •Subjects in Group 3 must match in gender, smoking status, age (±10 years), and body mass index [normal BMIs (18.00-24.99), overweight BMIs (25.00-30.99) and obese BMIs (31.00-40.00)] to Group 1 and/or 2;
- •Subjects must have normal renal function defined as eGFR ≥ 80 mL/min/m2 as calculated using the Modification of Diet in Renal Disease (MDRD) Equation (Appendix 18.3 );
- •Subjects must be in good health as determined by past medical history, physical examination, electrocardiogram, laboratory tests and urinalysis;
- •Vital signs (after 3 minutes resting in a semi-supine position) which are within the ranges shown below:
- •Body temperature between 35.0 - 37.5 °C;
- •Systolic blood pressure between 90 - 150 mmHg;
- •Diastolic blood pressure between 50 - 95 mmHg;
- •Pulse rate between 40 - 90 bpm.
排除标准
- •Smokers (use of tobacco products in the previous 3 months) unable or unwilling to limit consumption to 10 cigarettes per day or less while checked into the inpatient facility.
- •a. Note: Smoking will be a match criteria and the site should attempt to enroll an equal number of smokers and non-smokers into each group.
- •Exposure to any investigation drug, including placebo, within 30 days or 5 half-lives (whichever is longer) of dosing;
- •Donation or loss of 400 mL or more of blood within two months prior to dosing;
- •Significant illness within the two weeks prior to dosing;
- •Answer 'yes' to either Question 4 (Active Suicidal Ideation with Some Intent to Act, Without Specific Plan) or Question 5 (Active Suicidal Ideation with Specific Plan and Intent) on the "Suicidal Ideation" portion of the C-SSRS, or answer "yes" to any of the suicide-related behaviors (actual attempt, interrupted attempt, aborted attempt, preparatory act, or behavior) on the "Suicidal Behavior" portion of the Columbia Suicide Severity Rating Scale (C-SSRS); and the ideation or behavior occurred within the past 6 months;
- •Functioning renal transplant;
- •History within the past 2 years of clinically significant acute or chronic bronchospastic disease, including asthma and chronic obstructive pulmonary disease, treated or not treated;
- •Treatment with any drug known to cause major organ system toxicity (e.g., chloramphenicol or tamoxifen) during the 60 day preceding the Screening visit;
- •Participation in a previous BMS-214778/VEC-162 trial;
- •History of drug or alcohol abuse as defined in DSM-IV, Diagnostic Criteria for Drug and Alcohol Abuse, within the 12 months prior to screening or evidence of such abuse as indicated by the laboratory assays conducted during the screening and baseline visits. A positive drug screen in Groups 1 and 2 is acceptable if there is documentation that subjects have been prescribed the corresponding medication;
- •History of immunocompromise, including a positive HIV (ELISA and Western blot) test result;
- •A positive Hepatitis B surface antigen (HBsAg) test result;
- •Any surgical or medical condition which might significantly alter the absorption, distribution or excretion of any drug. The Investigator should be guided by evidence of any of the following:
- •History of clinically significant inflammatory bowel syndrome, gastritis, ulcers, gastrointestinal or rectal bleeding;
- •History of major gastrointestinal tract surgery such as gastrectomy, gastroenterostomy, or bowel resection;
- •History of pancreatic injury or pancreatitis;
- •History or presence of liver disease or liver injury as indicated by lab values such as SGOT, SGPT, GGT, alkaline phosphatase, or serum bilirubin 1.5 times greater than the upper limit of normal;
- •Clinically significant ECG abnormalities or vital sign abnormalities at screening or a history of unstable, severe, or clinically significant cardiovascular disease (e.g., myocardial infarction within previous 6 months, unstable angina, cardiac failure, second/third degree atrioventricular block);
- •Subjects taking any unapproved prescription or over-the-counter medications; all concomitant medications must be discussed with and approved by the sponsor prior to enrollment;
- •A known hypersensitivity to tasimelteon or drugs similar to tasimelteon including melatonin;
- •Pregnant or lactating females;
- •Inability to swallow the study medication whole;
- •Any other sound medical reason as determined by the clinical Investigator.
- •Groups 1 - 2 (renal impairment)
- •Subjects with clinically significant abnormal findings, not consistent with clinical disease, upon physical examination, ECG, or laboratory evaluation;
- •Evidence of progressive renal disease within 4 weeks prior to screening;
- •Acute renal failure or nephrotic syndrome;
- •Current hematuria of urologic origin;
- •Any significant change in chronic treatment medication as determined by the clinical Investigator.
- •Group 3 (healthy matched controls)
- •Use of unapproved prescription medication within 1 month of dosing and OTC medication within 14 days prior to dosing;
- •History or presence of impaired renal function as indicated by abnormal (>ULN) creatinine or BUN values or abnormal urinary constituents (e.g., albuminuria).
- •A positive hepatitis C test result.
研究组 & 干预措施
End Stage Renal Disease, dialysis
Experimental
eGFR <15 ml/min/1.73m^2
干预措施: Tasimelteon (Drug)
Severe renal impairment
Experimental
eGFR < 29 ml/min/1.73m^2
干预措施: Tasimelteon (Drug)
Healthy controls
Experimental
eGFR > 80 mL/min/1.73m^2 Matched to renally impaired subjects by age, gender, BMI, and smoking status
干预措施: Tasimelteon (Drug)
结局指标
主要结局
Tasimelteon pharmacokinetic parameters (AUC, Cmax, Tmax)
时间窗: Predose, 0.25, 1, 1.5, 2, 4, 6, 8, 12, 24, 30, and 36 hours post-dose
次要结局
- Pharmacokinetic parameters (AUC, Cmax, Tmax) of tasimelteon metabolites M3, M9, M11, M12, M13, and M14(Predose, 0.25, 1, 1.5, 2, 4, 6, 8, 12, 24, 30, and 36 hours post-dose)
- The percentage of tasimelteon and its metabolites that are removed by hemodialysis (AUC)(4, 6, 8 hours after dosing)
- The ratio of plasma protein bound versus unbound fractions of tasimelteon and metabolites M9, M11, M12, M13, and M14(0.5 and 3 hours post dose)
- Safety and tolerability as measured by spontaneous reporting of AEs, and clinically significant changes in laboratory parameters, ECG parameters, and vital signs(36 hours)
- The Columbia-Suicide Severity Rating Scale will be used to assess suicidal behavior and ideation.(once per day at Screening (approximately day -7), Day -1 (baseline), Day 2 (end of study))
研究者
研究点 (3)
Loading locations...
相似试验
已完成
1 期
Pharmacokinetics of Tasimelteon in Subjects With Mild or Moderate Hepatic ImpairmentHepatic ImpairmentNCT01271387Vanda Pharmaceuticals29
已完成
1 期
Effects of Smoking, Age and Body Size on Pharmacokinetics, Safety and Tolerability on Tasimelteon in Healthy SubjectsHealthy VolunteersNCT01477619Vanda Pharmaceuticals60
已完成
1 期
Pharmacokinetics of Tasimelteon Alone and in Combination With a CYP3A4 Inhibitor, Ketoconazole, or a CYP3A4 Inducer, Rifampin.HealthyNCT01637636Vanda Pharmaceuticals48
已完成
1 期
A Study to Assess the Effect Tasimelteon on the Cytochrome P450 3A4 and 2C8 Enzymes in Healthy SubjectsHealthy VolunteersNCT01402076Vanda Pharmaceuticals24
已完成
不适用
Comparative Randomized, Single Dose, Two-way Crossover Open-label Study to Determine the Bioequivalence of Gabapentin From Nerpentin 600 mg (Test ) F.C.T (Aman Pharma ,Egypt.) and Gabapentin From Neurontin 300 mg (Referance ) H.G.C. ( Pfizer Egypt)HealthyNCT04805827Pharma Guide CRO34